1. Home
  2. RSSS vs GANX Comparison

RSSS vs GANX Comparison

Compare RSSS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Research Solutions Inc

RSSS

Research Solutions Inc

HOLD

Current Price

$2.31

Market Cap

76.6M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.82

Market Cap

76.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSSS
GANX
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.6M
76.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
RSSS
GANX
Price
$2.31
$1.82
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$5.00
$7.50
AVG Volume (30 Days)
51.0K
709.9K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
130.77
31.46
EPS
0.07
N/A
Revenue
$28,793,922.00
$55,180.00
Revenue This Year
$1.81
N/A
Revenue Next Year
$5.73
N/A
P/E Ratio
$33.29
N/A
Revenue Growth
2.77
N/A
52 Week Low
$2.00
$1.41
52 Week High
$4.12
$4.34

Technical Indicators

Market Signals
Indicator
RSSS
GANX
Relative Strength Index (RSI) 50.92 50.05
Support Level $2.17 $1.66
Resistance Level $2.37 $2.15
Average True Range (ATR) 0.08 0.14
MACD 0.01 0.00
Stochastic Oscillator 53.85 26.79

Price Performance

Historical Comparison
RSSS
GANX

About RSSS Research Solutions Inc

Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: